An open-label, single-arm study to investigate the efficacy of Favipiravir on Lassa Fever for Post Exposure Prophylaxis - FavLap

Morioka Shinichiro0 个研究点目标入组 5 人开始时间: 2023年12月1日最近更新: 2024年1月22日

研究概览

暂无简介。

•1)Has given written consent to participate in the study
•2)18 years of age or older at the time consent is given
•3)Has a skin injury from a sharp instrument contaminated (or suspicious to be so) with Lassa virus.
•4)Whose the mucous membranes or damaged skin has been contacted with a sample contaminated with Lassa virus.
•5)Contacted with a patient with Lassa fever (or who is suspicious to be so) within a confined space without wearing appropriate protective equipment.
•6)Performed emergent intervention such as cardiopulmonary resuscitation without wearing appropriate protective equipment.
•7)Other situation in relation to 1)-4) above, those considered to be adequate for post exposure prophylaxis by principle/sub investigator.

•1) Prengant patient
•2) Those who are breast-feeding and cannot promise to stop breast-feeding during and for 7 days after the end of administration
•3) Unable to commit to using an effective contraceptive method during treatment and for 14 days after completion of treatment for women and during treatment and for 7 days after completion of treatment for men
•4) Women who cannot commit to not donating eggs during treatment and for 14 days after completion of treatment, or men who cannot commit to not donating sperm for reproductive purposes during treatment and for 7 days after completion of treatment
•5) Those who cannot promise not to have sexual intercourse with pregnant women during and for 7 days after completion of administration
•6) Persons with a history of severe hypersensitivity to the ingredients of Favipiravir
•7) More than 22 days after exposure
•8) Those that have already developed Lassa fever
•9) Judged illegible to participate in the study by the principal investigator or sub-investigator

发起方

Morioka Shinichiro